DNDi - NewsLetter


HOME
ABOUT DNDi EDITORIAL: "NECT is a Success but Many Challenges Still Remain" CALENDAR HOW YOU CAN HELP DNDi?
Nifurtimox-Eflornithine Combination Therapy: An Improved Treatment for Sleeping Sickness Gerardo Priotto : Portrait A Major Step Forward in Improving Treatment Options for HAT NECT: Next Steps Sleeping Sickness [Human African Trypanosomiasis-HAT] What DNDi Does to Address Sleeping Sickness HAT Projects Supported by Public and Private Funds TDR investigates NECT in Uganda The Key Role Played by the HAT Platform Challenges of Establishing and Monitoring a GCP Trial in Remote Settings Challenges to Follow HAT Patients Evolution After A Hope for Surviving Sleeping Sickness: Joseph’s Story Thank you Angèle Malaria: ASAQ Obtains WHO Prequalification Chagas Disease: Agreement between Lafepe and DNDi on Safe, Easy-to-Use Treatment for Children Visceral Leishmaniasis: 11th LEAP meeting takes place in Addis Ababa to Discuss VL Strategy Plan DNDi Event: Indian Scientists Catalyse Efforts in Research and Development for New Treatments for Neglected Diseases BBC Documentary on Sleeping Sickness Fexinidazole Progresses into Clinical Development Discovery Programmes for HAT Contacts DNDi Credits

Chagas Disease: Agreement between Lafepe and DNDi on Safe, Easy-to-Use Treatment for Children

A partnership agreement signed on 21 July 2008 between Drugs for Neglected Diseases initiative (DNDi) and the Pharmaceutical Laboratory of Pernambuco (Lafepe) will deliver the first paediatric formulation of benznidazole, the most widely used drug for the treatment of Chagas disease, at cost and for worldwide distribution. Children infected by Chagas disease, endemic in 21 countries in Central and South America, will soon have access to a treatment tailored to their needs. The first paediatric formulation of benznidazole will be made available to patients in 2010. The drug will be sold with no profit to the institutions involved in its development, and will be available for distribution worldwide.

See also:

Published by Drugs for Neglected Diseases Initiative - 15 Chemin Louis-Dunant 1202 Geneva Switzerland - Photo credits: DNDi unless otherwise stated - Editor: Sadia Kaenzig - Tel: +41 22 906 9230 - Fax: +41 22 906 9231 - www.DNDi.org